Skip to main content
Glama

Kegg

by io.github.pipeworx-io

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.7/5.0
Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true, idempotentHint=true, etc. The description adds value by explaining the data sources (SEC EDGAR/XBRL for companies, FAERS for drugs), handling of off-calendar fiscal years, and output format (paired data with citation URIs). No contradictions detected.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is detailed yet efficient, front-loaded with trigger phrases and key advantages. Slightly long but every sentence serves a purpose. Could be trimmed slightly but remains clear and well-organized.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given no output schema, the description adequately explains return values (revenue, net income, etc. for companies; adverse-event counts, FDA approvals, trials for drugs) and provides citation information. Covers edge cases (off-calendar fiscal years) and replacement value (replaces 8-15 lookups).

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but description enhances understanding by explaining the type enum with concrete examples (tickers/CIKs for company, drug names for drug), constraints (2-5 items), and behavior like sorting by primary metric so rank queries work intuitively.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states it performs side-by-side comparison of 2-5 companies or drugs, with specific trigger phrases like 'compare X and Y' and 'rank these companies'. It distinguishes itself from siblings like entity_profile (single entity lookups) by emphasizing parallel comparison.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Explicitly states 'ALWAYS PREFER over sequential single-pack lookups' and provides concrete trigger phrases. It also explains when to use company vs drug type and how results are sorted for ranking queries.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Kegg toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation3/5

Most tools have clearly described distinct purposes, but several overlap: ask_pipeworx and ask_pipeworx_beta are explicitly identical right now, and ask_pipeworx_grounded, deep_research, discover_tools, and suggest_questions all occupy neighboring query/discovery territory. The Polymarket and memory tool families, by contrast, are well differentiated.

Naming Consistency3/5

All names are snake_case and readable, but the set mixes verb-first names (ask_pipeworx, compare_entities, resolve_entity, validate_claim) with noun-phrase names (entity_profile, bet_research, recent_alerts, polymarket_arbitrage) and brand prefixes (pipeworx_*, polymarket_*). There is no consistent verb_noun pattern across the toolkit.

Tool Count2/5

34 tools is well beyond the heavy range, and the count is especially inappropriate because the server is named Kegg but only find, get_entry, and list_database relate to KEGG bioinformatics. The remaining 31 tools span unrelated domains (generic data research, prediction markets, memory, subscriptions, AI visibility, npm scanning), making the scope feel like several products merged into one.

Completeness2/5

As a KEGG server, the surface is severely thin: three read-only tools with no pathway mapping, sequence search, or cross-reference utilities. The Pipeworx research and Polymarket betting subsystems are more complete, but their presence under a Kegg server makes the overall surface incoherent rather than complete.

Resources